Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist December 8, 2025 8:30 AM EST
Company Participants
Danielle Keatley Raymond Stevens - CEO & Director Blai Coll - Chief Medical Officer
Conference Call Participants
Evan Seigerman - BMO Capital Markets Equity Research Seamus Fernandez - Guggenheim Securities, LLC, Research Division Terence Flynn - Morgan Stanley, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Samantha Semenkow - Citigroup Inc., Research Division David Risinger - Leerink Partners LLC, Research Division Jial…
Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist December 8, 2025 8:30 AM EST
Company Participants
Danielle Keatley Raymond Stevens - CEO & Director Blai Coll - Chief Medical Officer
Conference Call Participants
Evan Seigerman - BMO Capital Markets Equity Research Seamus Fernandez - Guggenheim Securities, LLC, Research Division Terence Flynn - Morgan Stanley, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Samantha Semenkow - Citigroup Inc., Research Division David Risinger - Leerink Partners LLC, Research Division Jiale Song - Jefferies LLC, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Hardik Parikh - JPMorgan Chase & Co, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Patrick Dolezal - LifeSci Capital, LLC, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Structure Therapeutics top line results from the aleniglipron Phase II Access Program. [Operator Instructions] Please be advised that today’s conference is being recorded. I’d now like to hand the conference over to Danielle Keatley, Head of Investor Relations. Please go ahead.
Danielle Keatley
Thank you, and good morning. Earlier today, we issued a press release providing top line results from Structure Therapeutics access clinical program for aleniglipron, our oral small molecule GLP-1 receptor agonist. A copy of this release and the presentation to accompany the call are available on the Investor Relations section of our website. Before we get started, I would like to remind everyone that some of the statements that we make on this call and information presented in the slide deck include forward-looking statements, which you see here. These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially.